Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
161 hedge funds and large institutions have $1.6B invested in Revance Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
25% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 44
8% more funds holding
Funds holding: 149 → 161 (+12)
5% more capital invested
Capital invested by funds: $1.53B → $1.6B (+$69.2M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
41% less call options, than puts
Call options by funds: $6.68M | Put options by funds: $11.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$17.6M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$11.4M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
+$4.91M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.32M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$41.1M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$8.17M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$7.66M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.5M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$6.54M |
RVNC Hedge Fund Activity: Q2 2021 in Review
161 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2021, worth a combined $1.6B — up 4.5% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RVNC positions and 13 closed out — a net gain of 12 holders — while 55 added to existing stakes and 44 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $17.6M. The largest seller was Essex Woodlands Management, cutting an estimated $41.1M.
- 161 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2021, up from 149 in Q1 2021.
- Funds reported $1.6B of Revance Therapeutics, Inc. stock for Q2 2021, up 4.5% quarter-over-quarter.
- 25 funds opened new Revance Therapeutics, Inc. positions in Q2 2021 and 13 closed out, a net change of +12 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2021 was JP Morgan Chase, an estimated $17.6M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2021 was Essex Woodlands Management, an estimated $41.1M sold.
Based on aggregated 13F filings for Q2 2021.